ClinicalTrials.gg

Program

Liposomal Bupivacaine

Also written as “EXPAREL”, “bupivacaine liposome injectable suspension” and “Exparel”.

Its studies are mostly in Pain, Postoperative · Pain · Bunion · Intestinal Obstruction · Hallux Valgus, led by 4 companies.

Furthest: phase 4, since Oct 23, 201139 company-led studies, 1 open or runningNext primary completion: Jan 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pacira BioSciences361 open or runningphase 4since Oct 23, 2011Oct 23, 2011Jan 2027phase 1 · NCT06271265
Heron Therapeutics10 open or runningphase 4since Sep 23, 2019Sep 23, 2019none ahead
Jiangsu HengRui Medicine10 open or runningphase 1since Dec 1, 2025Dec 1, 2025none ahead
Nuance Pharma (shanghai)10 open or runningphase 1since Nov 5, 2019Nov 5, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 24 studies since Oct 23, 2011.

  1. Sep 19, 2018Phase 4 study in AgnosiaPacira BioSciences · NCT03853694 · 167 enrolled · United States
  2. Sep 20, 2018Phase 3 study in Postoperative Pain ManagementPacira BioSciences · NCT03682302 · 98 enrolled · United States
  3. Apr 19, 2019Phase 4 study in Postoperative Pain ManagementPacira BioSciences · NCT03927911 · 65 enrolled · United States
  4. May 14, 2019Phase 4 study in Hip FracturesPacira BioSciences · NCT03955458 · United States
  5. May 15, 2019Phase 3 study in BunionPacira BioSciences · NCT03954639
  6. Jun 25, 2019Phase 1 study in BunionPacira BioSciences · NCT04002089 · 45 enrolled · United States
  7. Sep 23, 2019Heron Therapeutics’ first study: phase 4 study in AgnosiaNew to Heron TherapeuticsHeron Therapeutics · NCT04102267 · 32 enrolled · United States
  8. Nov 5, 2019Nuance Pharma (shanghai)’s first study: phase 1 study in Healthy SubjectsNew to Nuance Pharma (shanghai)Nuance Pharma (shanghai) · NCT04158102 · 20 enrolled · China
  9. Nov 18, 2019Phase 1 study in HealthyPacira BioSciences · NCT04173611 · 20 enrolled · United States
  10. Feb 29, 2020Phase 1 study in Breast AugmentationPacira BioSciences · NCT04293809 · 30 enrolled · United States
  11. Aug 4, 2020Phase 3 study in BunionPacira BioSciences · NCT04518462 · 121 enrolled · United States
  12. Nov 15, 20212 phase 3 studiesPacira BioSciences · NCT05157841, NCT05139030
  13. Jan 18, 2024Phase 1 study in Pain, PostoperativePacira BioSciences · NCT06271265 · 48 planned · United States
  14. Dec 1, 2025Jiangsu HengRui Medicine’s first study: phase 1 study in Postoperative Local AnalgesiaNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT07279155 · 36 enrolled · China

Ahead

  1. Jan 2027Primary completion: phase 1 study in Pain, PostoperativePacira BioSciences · NCT06271265

TargetBeta

SCN4A →read by rule
“Sodium channel protein type IV alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker”ChEMBL 37, by rule

Other programs on SCN4A

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
RanolazineruleGilead Sciencesphase 426
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37

Studies

All 39 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07279155Postoperative Local Analgesia · China1CompletedJiangsu HengRui MedicineJul 21, 202536
NCT06271265Pain, Postoperative · United States1RecruitingPacira BioSciencesJan 202748
NCT05157841Hallux Valgus · United States3CompletedPacira BioSciencesAug 17, 2022185
NCT05139030Osteoarthritis, Knee · United States3CompletedPacira BioSciencesJul 11, 2022167
NCT04518462Bunion · United States3CompletedPacira BioSciencesApr 5, 2021121
NCT04293809Breast Augmentation · United States1CompletedPacira BioSciencesJan 15, 202030
NCT04173611Healthy · United States1TerminatedPacira BioSciencesDec 7, 202020
NCT04158102Healthy Subjects · China1CompletedNuance Pharma (shanghai)Dec 17, 201920
NCT04102267Agnosia · United States4CompletedHeron TherapeuticsSep 3, 201832
NCT04002089Bunion · United States1CompletedPacira BioSciencesDec 2, 201945
NCT03954639Bunion3WithdrawnPacira BioSciencesSep 20200
NCT03955458Hip Fractures · United States4WithdrawnPacira BioSciencesMay 20200
NCT03927911Postoperative Pain Management · United States4TerminatedPacira BioSciencesAug 4, 202065
NCT03682302Postoperative Pain Management · United States3CompletedPacira BioSciencesAug 30, 201998
NCT03853694Agnosia · United States4CompletedPacira BioSciencesJan 9, 2020167
NCT03485014Postoperative Pain Management · United States1CompletedPacira BioSciencesFeb 12, 201915
NCT03428984Postoperative Pain Management · United States1TerminatedPacira BioSciencesSep 28, 20185
NCT03176459Agnosia · United States4CompletedPacira BioSciencesNov 20, 2018186
NCT02985762Agnosia · United States1CompletedPacira BioSciencesSep 201715
NCT03015961Postoperative Pain Management · United States4TerminatedPacira BioSciencesOct 30, 201738
NCT02713490Pain · United States4CompletedPacira BioSciencesFeb 8, 2017140
NCT02713230Pain · United States, Belgium, Denmark3CompletedPacira BioSciencesJul 7, 2017156
NCT02713178Pain · United States, Belgium, Denmark3CompletedPacira BioSciencesJun 30, 2017232
NCT02353754Pain · United States4TerminatedPacira BioSciencesJun 201512
NCT02255500Pain · United States4CompletedPacira BioSciencesMar 201523
NCT02210247Healthy Volunteers · United States1CompletedPacira BioSciencesSep 201460
NCT02199574Pain · United States4CompletedPacira BioSciencesApr 201512
NCT02142829Obesity · United States4CompletedPacira BioSciencesMar 2013101
NCT02058290Intestinal Obstruction · United States4TerminatedPacira BioSciencesSep 2012122
NCT01919190Pain · United States4TerminatedPacira BioSciencesDec 201367
NCT01919606Pain, Postoperative4TerminatedPacira BioSciencesOct 20121
NCT01802411Pain, Postoperative · United States, Bulgaria, Czechia and more3CompletedPacira BioSciencesJun 2013191
NCT01801124Hernia · United States4CompletedPacira BioSciencesDec 201213
NCT01683071Pain, Postoperative · United States3CompletedPacira BioSciencesDec 2013297
NCT01582477Pain, Postoperative · United States4CompletedPacira BioSciencesMay 201224
NCT01509807Retraction of Colostomy · United States4CompletedPacira BioSciencesOct 201233
NCT01509638Retraction of Colostomy · United States4CompletedPacira BioSciencesOct 201247
NCT01507233Intestinal Obstruction · United States4TerminatedPacira BioSciencesJul 20125
NCT01507246Intestinal Obstruction · United States4CompletedPacira BioSciencesJul 201242

How it is read

Names in the registry

  • “EXPAREL”, 15 entries
  • “bupivacaine liposome injectable suspension”, 4 entries
  • “Exparel”, 3 entries
  • “Exparel Injectable Product”, 2 entries
  • “EXPAREL 266 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.